Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 4Neoplasm Metastasis 3Rectal Neoplasms 2Leukemia, Myeloid, Acute 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neoplasms 1Myeloproliferative Disorders 1Multiple Myeloma 1Lung Neoplasms 1Lung Cancer - Malignant Pleural Mesothelioma 1Liver Neoplasms 1Leukemia 1Hematologic Neoplasms 1Gastrointestinal Stromal Tumors 1Fallopian Tube Neoplasms 1Esophagogastric Cancer 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Blast Crisis 1

Interventions

fludarabine phosphate 58Cyclophosphamide 54Peripheral Blood Stem Cell Transplantation 49Mycophenolic Acid 39Busulfan 38Tacrolimus 37Cyclosporine 33Antilymphocyte Serum 33Whole-Body Irradiation 32Filgrastim 28Methotrexate 27Radiotherapy 20Melphalan 18Cytarabine 17fludarabine 16Etoposide 16Methylprednisolone 14ruxolitinib 11sargramostim 9Flow Cytometry 9Cyclosporins 9Cord Blood Stem Cell Transplantation 9Alemtuzumab 9thymoglobulin 8Sirolimus 8Psychiatric Rehabilitation 8Granulocyte Colony-Stimulating Factor 8Azacitidine 8merphos 7Decitabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Myeloproliferative Disorders × STA 9090 × Clear all
NCT00858572 2014-09-18

STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders

Synta Pharmaceuticals Corp.

Phase 1 Completed
31 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡